Vir Biotechnology’s Elebsiran‑Tobevibart combo meets Phase 3 endpoints, offering a monthly subcutaneous cure for chronic hepatitis delta and a new hope for HBV‑co‑infected patients.
Church & Dwight’s latest SEC filings reveal insider confidence: execs and directors are buying shares and holding options that align with long‑term value, reinforcing strong governance and investor trust.
Procter & Gamble removes its 0.110 % 2026 notes from the NYSE after full redemption, illustrating its debt‑management strategy and market‑compliance moves.
Unilever PLC discloses a minor Rule 144 sale of its ADS, detailing the transaction, broker, and insider officer, to boost U.S. liquidity while maintaining strict SEC compliance.
Church & Dwight insider trades show disciplined liquidity management, strong R&D focus and transparent compliance—insight for investors on future growth prospects.
Unicharm’s latest nine‑month results show revenue growth but margin pressure; the firm’s upgraded 2026 outlook hinges on premium, eco‑friendly lines and Southeast Asia expansion, balanced by rising debt and regulatory risks.